288 Result(s)

The rise of drug-resistant pathogens is a real threat.
Human Health Innovation

“Rapid progress towards clinical candidates”

Michel Pairet, Member of the Board of Managing Directors, explains why Boehringer Ingelheim expands its commitment to fighting drug resistant infections with a new joint venture.
Fibroneer Illustration
Pulmonary Fibrosis

Addressing the urgent need for new treatments for people living with idiopathic pulmonary fibrosis (IPF) and other progressive fibrosing interstitial lung diseases (ILDs)

Donald Zoz, M.D., Director and Senior Clinical Program Leader for Pulmonary Fibrosis, discusses the FIBRONEER™ global clinical program.
Patient Centricity

Our position

Boehringer Ingelheim’s position on compassionate use of investigational medications.